IL2 and Miyoshi myopathy: A randomized controlled phase III study is currently assessing if TIL infusion preceded by non-myeloablative chemotherapy and followed by HD IL-2 can produce an improved PFS as compared with ipilimumab in 168 MM patients (NCT02278887).